Patient-Focused Drug Development: US FDA 'Needs To Be Brave,' Tell Sponsors What Works Best

At public workshop, FDA says it will be flexible on clinical outcome assessments but stakeholders want agency to specify no-no's; digital health technology is appropriate to get more accurate endpoints, agency says.